Lantheus (NASDAQ:LNTH) Hits New 52-Week High – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high during trading on Thursday . The stock traded as high as $104.50 and last traded at $104.32, with a volume of 1223938 shares. The stock had previously closed at $100.24.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LNTH. Citizens Jmp boosted their target price on Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research note on Friday, May 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Finally, Mizuho upped their price objective on Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Price Performance

The company has a 50 day moving average price of $90.68 and a 200-day moving average price of $76.64. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The company has a market cap of $6.81 billion, a price-to-earnings ratio of 25.19 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the prior year, the firm posted $1.53 earnings per share. The firm’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 4.39 EPS for the current fiscal year.

Institutional Trading of Lantheus

Several institutional investors have recently added to or reduced their stakes in LNTH. EverSource Wealth Advisors LLC boosted its holdings in Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 698 shares during the last quarter. First Trust Advisors LP boosted its holdings in Lantheus by 37.4% in the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after acquiring an additional 19,008 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in Lantheus by 22.6% in the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 500 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in Lantheus by 88.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 1,591 shares during the last quarter. Finally, Osterweis Capital Management Inc. bought a new stake in Lantheus in the second quarter valued at approximately $36,000. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.